Phase 2 study V940 personalized mRNA vaccine for patient-specific cancer immune targeting

This Phase 2 study evaluates whether combining V940 with standard BCG extends event-free survival compared to BCG alone, as well as the efficacy of V940 monotherapy in high-risk non-muscle invasive bladder cancer. Conducted at sites such as Madrid, New York, and Los Alamitos with Merck Sharp & Dohme LLC sponsoring, the trial explores a novel personalized mRNA immunotherapy approach in a first-in-patient setting.